PlainMeds provides educational information only. This is not medical advice. Always consult your doctor or pharmacist.

Drug side effects

cyclosporine Side Effects

The reactions most often reported to the FDA for cyclosporine (also sold as Neoral, Sandimmune), with demographics, serious outcomes, and reporting trends.

Data updated 2026-05-15

106,440
FAERS reports

Data from the FDA Adverse Event Reporting System (FAERS), 1994 to 2025. A FAERS report records a temporal association, not proof of cause. See our methodology for how figures are compiled and de-duplicated.

The most commonly reported side effects of cyclosporine come from 106,440 reports to the FDA, broken down here by frequency, patient demographics, and serious outcomes.

This page analyzes 106,440 reports to the FDA Adverse Event Reporting System (FAERS) for cyclosporine (Neoral): the reactions reported most often, who reported them, serious outcomes such as hospitalization, and year-over-year trends. A FAERS report does not prove the drug caused the effect, and report volume tracks how widely a drug is used, not how likely an effect is for any one person. Educational information, not medical advice.

Total Reports

106,440

Reports Mentioning Death

13,961

13.1% of reports — not proof the medicine caused the death

Hospitalizations

27,207

25.6% of reports

Top Indication

Product Used For Unknown Indication

Most Reported Adverse Reactions

EYE IRRITATION
7,786
PYREXIA
4,064
EYE PAIN
3,808
NAUSEA
3,623
DIARRHOEA
3,562
HEADACHE
3,558
FATIGUE
3,369
PNEUMONIA
3,267
PAIN
3,144
CONDITION AGGRAVATED
3,042
VISION BLURRED
2,841
RASH
2,650
PRURITUS
2,579
DYSPNOEA
2,548
DEATH
2,437
OCULAR HYPERAEMIA
2,376
ARTHRALGIA
2,351

Who Reports Side Effects

Gender Distribution

Female 57,699 (61%)
Male 36,338 (38%)
Unknown 623

Age Distribution

0-17 8,868 (14%)
18-44 14,124 (22%)
45-64 23,625 (37%)
65-74 11,178 (17%)
75+ 6,820 (11%)

Reporting Trend by Year

1994 2025

Reactions in Death Reports

Top reactions reported in 13,961 reports where death was an outcome. These are voluntarily reported and do not establish causation.

Reaction Reports
DEATH 2,411
SEPSIS 1,229
PNEUMONIA 1,079
PYREXIA 985
RESPIRATORY FAILURE 793
INFECTION 750
GRAFT VERSUS HOST DISEASE 745
SEPTIC SHOCK 735
CYTOMEGALOVIRUS INFECTION 714
MULTIPLE ORGAN DYSFUNCTION SYNDROME 697
MULTI-ORGAN FAILURE 564
RENAL FAILURE 533
ACUTE GRAFT VERSUS HOST DISEASE 499
DIARRHOEA 483
DYSPNOEA 439
EPSTEIN-BARR VIRUS INFECTION 387
RENAL IMPAIRMENT 378

Reactions in Hospitalization Reports

Top reactions in 27,207 reports where hospitalization was an outcome.

Reaction Reports
PYREXIA 2,529
PNEUMONIA 1,662
DIARRHOEA 1,558
NAUSEA 1,418
DYSPNOEA 1,326
VOMITING 1,248
HEADACHE 1,170
FATIGUE 1,168
BLOOD CREATININE INCREASED 1,163
CONDITION AGGRAVATED 1,069
SEPSIS 1,064
PAIN 1,046
ACUTE KIDNEY INJURY 1,027
HYPERTENSION 983
RENAL FAILURE 966
ANAEMIA 945
MALAISE 926

Compare cyclosporine vs adapalene →

What the FAERS Data Reveals About cyclosporine Side Effects

The FDA Adverse Event Reporting System (FAERS) contains 106,440 voluntary reports linked to cyclosporine and its brand equivalents (Neoral, Sandimmune, Restasis), spanning 1994 through 2025. Of those, 13,961 (13.1%) listed death as an outcome and 27,207 (25.6%) involved hospitalization. The most common indication reported alongside adverse events was Product Used For Unknown Indication.

Demographic breakdowns help contextualize who is being exposed to the drug. Of reports with known sex, 61% were female and 38% male; age distribution skews toward 45-64, with 23,625 reports in that bracket. The single most reported reaction is eye irritation with 7,786 submissions, followed by pyrexia and eye pain.

How to read these numbers

FAERS is a signal-detection tool, not a scorecard. Reports are voluntary, and a single case may list multiple suspect drugs, so numbers above should not be read as incidence rates or per-patient risk. Widely prescribed drugs naturally accumulate more reports than niche therapies even when individual risk is low. These aggregates are useful for spotting patterns that merit further pharmacovigilance, not for choosing between medications. This page is for educational reference only and is not medical advice, speak with a licensed clinician about any side-effect concerns.